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Summary 
NH2-terminal glycine myristyl acylation is a cotranslational modification that affects both protein 
localization  and function. However,  several proteins that lack NH2-terminal glycine residues, 
including the interleukin 1 (Ibl) precursors, also contain covalently linked myristate.  To date, 
the site(s) of acylation of these proteins has not been determined. During an evaluation of Ibl 
acylation,  it  was  observed  that  [3H]myristate-labded  human monocyte lysates contained a 
prominent 26-kD myristylated protein, which was identified as the tumor necrosis factor ce (TNF) 
precursor protein on the basis of specific immune precipitation.  Radioimmunoprecipitates from 
the supernates of labeled monocytes indicated that the processed or mature 17-kD form of TNF 
does not contain myristate,  suggesting that the site of acylation occurs within the 76-amino 
acid propiece  of the precursor molecule.  As the TNF precursor does not contain an NH2- 
terminal glycine, we hypothesized that myristyl acylation occurs on the N-e-NH2 groups of 
lysine, of which two are present in the propiece (K19K20). Synthetic peptides were designed to 
include all seven lysine residues present  within the entire 26-kD TNF precursor,  and used in 
an in vitro myristyl acylation assay containing peptide,  myristyl-CoA, and monocyte lysate as 
a source of enzyme. Analysis of reaction products by reverse phase high performance liquid 
chromatography and gas phase sequencing demonstrated the exclusive myristyl acylation of K19 
and  K20, consistent  with  the  presence  in  monocytes of a  specific lysyl  N-e-NH2-myristyl 
transferase activity.  The acylated lysine residues are located immediately downstream from a 
hydrophobic,  probable membrane-spanning segment of the propiece. Specific myristyl acylation 
of the TNF propiece may facilitate membrane insertion or anchoring of this critical inflammatory 
mediator. 
mong the many modifications of newly synthesized pro- 
teins, cotranslational  acylation with myristic acid has 
received considerable attention as an important determinant 
of protein function and intracellular localization (for review, 
see reference 1). For most myristylated proteins studied thus 
far, acyhtion occurs via the formation of an amide bond linking 
the fatty acid to an NHz-terminal glycine residue after the 
removal of the initiator methionine. This process has been 
weU characterized and the enzyme responsible, myristyl CoA: 
protein N-myristyl transferase (NMT), 1 has been cloned (2). 
However, in  a few cases myristylated proteins  have been 
identified that lack the correctly positioned NHz-terminal 
glycine strictly required for acylation by NMT. These pro- 
teins include the insulin receptor, the/~ Ig heavy chain, and 
1 Abbreviation used in this paper: NMT, N-myristyl transferase. 
the Ibl oc and B precursors (3-5). All of these proteins are 
myristylated by an undescribed enzymatic mechanism that 
does not involve acylation on NH2-terminal glycines. One 
potential alternative mechanism for myristyl acylation would 
be the myristylation of internal lysine residues, using the free 
e-amino groups to form the characteristic amide bonds. Ac- 
ylation of internal lysine residues with long chain fatty acids 
has been shown to enhance binding of pancreatic phospholi- 
pase A2 to its substrate (6, 7), but as yet, the myristylation 
of internal lysine residues as a discrete, cotranslational  pro- 
tein modification has not been demonstrated. 
TNF is a cytokine active in mediating cachexia, tumor 
regression,  septic shock, autoimmunity, and complications 
in infections  such as HIV-1, cerebral malaria,  and bacterial 
meningitis (reviewed in reference 8). TNF is translated as a 
26-kD precursor molecule that is subsequently processed by 
unclear mechanisms to an extracellularly active, 17-kD ma- 
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rein can act as a plasma membrane-associated protein that 
mediates inflammation by direct cell-to-cell contact (10, 11). 
We report here that 26-kD  TNF is myristylated and that 
the acylation occurs via amide bond formation with two 
specific e-amino groups of internal lysine residues  present 
within the 76-amino acid propiece of the molecule. Myristyl 
acylation within this region may facilitate the membrane lo- 
calization or insertion of the precursor molecule. 
Materials and Methods 
Reagents.  Lipid A, purified from the Salmonella minnesota lk595 
strain, was obtained from Ribi Immunochem (Hamilton, MT). 
The lipid A was prepared as a stock solution of 1 #g/ml in RPMI 
1640 supplemented with 0.1% defatted BSA. Immediately before 
use, the stock solution of lipid A was briefly sonicated on ice. Pan- 
sorbin (fixed protein A-bearing Staphylococcus aurens) for radioim- 
munoprecipitation was obtained from Calbiochem-Behring Corp. 
(La Jolla, CA). Media and heat-inactivated FCS were from Gibco 
Laboratories (Grand Island, NY).  [3sS]Methionine (1,300 Ci/ 
mmol),  [3SS]cysteine (800 Ci/mmol),  and  [3H]myristate (22 
Ci/mmol) were obtained from New England Nuclear (Boston, 
MA). The murine monoclonal anti-human TNF antibody TNF-E 
was obtained from Genentech Inc. (S. San Francisco, CA). This 
IgG1 antibody had a neutralization titer of >5  x  10  s U/ml and 
an endotoxin concentration  of  4 EU/ml by Limulus antilipopolysac- 
charide assay. Human recombinant TNF was obtained from Gen- 
zyme (Cambridge, MA). 
Preparation of Cells and Cytosol.  Heparinized  blood from normal 
donors was diluted 1:1 with PBS, pH 7.2, before separation over 
Ficoll-Hypaque cushions (Sigma Chemical Co., St. Louis, MO) 
by centrifugation for 15 min at 2,000 g. The mononuclear cell in- 
terface was collected, washed three times in calcium-free  PBS, and 
distributed to 100-ram plastic dishes at a concentration of 5  x 
106 cells/ml in RPMI 1640 containing 5% FCS. After incubation 
at 37~  in 5% CO2 for 2 h, nonadherent cells were removed by 
vigorous washing.' The adherent monolayers consisted of >95% 
monocytes as assessed  by nonspecific  esterase staining and phago- 
cytosis of zymosan. For preparation of crude cytosolic fractions, 
monocytes were suspended in TE buffer (10 mM TRIS-C1, pH 
7.6, 1 mM EDTA) containing protease inhibitors (5 mM EDTA, 
0.2 mM PMSF, 2/~M pepstatin), and subjected to three cycles of 
freeze-thawing at -80~  Unlysed cells and nuclei were removed 
by centrifugation at 2,000 g and lysates were stored at  -80~ 
Experimental  Protocol.  For labeling with [3SS]methionine or 
[3sS]cysteine, washed layers of monocytes were incubated for 60 
min in methionine- or cysteine-deficient  medium. The medium was 
removed and replaced with fresh medium containing 100/~Ci/ml 
of  labded methionine or cysteine  as indicated. Experimental groups 
were stimulated for 4 h with 100 ng/ml lipid A. After incubation, 
the culture supernatants were removed, centrifuged at 400 g for 
10 min, supplemented  with protease  inhibitors as above, and frozen 
at  -80~  Monocyte layers were washed twice with cold PBS, 
scraped into microfuge tubes, and centrifuged at 10,000 g for 5 
min. The cell pellets were washed an additional two times with 
cold PBS before preparation for electrophoretic  analysis  or immune 
precipitation. For labeling with [3H]myristate, the fatty acid was 
dried under argon and brought into solution at 25/zCi/ml by soni- 
cation in medium supplemented with 0.1% defatted BSA. After 
incubation, the cell  layers  and supernatants  were processed as above. 
Immune Precipitation.  Cell pellets from [3H]myristate-labeled 
human monocytes were lysed in a equal volume of 2 x lysis  buffer 
consisting of (final concentrations) 2% NP-40, 0.15 M NaC1, 10 
mM NaH2PO4, pH 7.2, 0.68 M sucrose, and protease inhibitors 
as above. The lysates were incubated on ice for 30 min, sonicated 
with three 10-s bursts on ice at a power setting of five (Bronson 
Ultrasonics, Danbury, CT), and centrifuged at 10,000g for 15 min. 
For immune precipitation of radiolabeled  cellular TNF, the cell 1)- 
sates were precleared by incubation at 4~  overnight with 10% 
(vol/vol) Pansorbin. The cleared lysates were then incubated for 
18 h at 4~  with 2.5/~g/ml of murine monoclonal anti-TNF IgG. 
TNF antigen-antibody  binding was competed  by addition  of  purified 
recombinant human TNF in concentrations from 0.1 to 1/~g/ml. 
Nonimmune routine IgG was used as a negative control. After in- 
cubation, 10% Pansorbin was added and the bound immune com- 
plexes were recovered by centrifugation. The pellets were washed 
five times in large volumes of  wash buffer containing 0.5 % NP-40, 
0.45 M NaC1, and 50 mM Tris/HC1, pH 8.3. The pellets were 
resuspended in IEF sample buffer (9.3 M urea, 5 mM K2CO3, 2% 
NP-40, 2% 3-10 ampholines, and 30 mM DTT). After a 2-h incu- 
bation at 4~  the samples were centrifuged and analyzed  by two- 
dimensional  electrophoresis. The proteins were separated  in the first 
dimension on 0.4 mm ultrathin polyacrylamide  gels according to 
Goldsmith et al. (12), using 1.4% 4-6 ampholines and 0.6% 3-10 
ampholines (LKB Instruments, Inc., Bromma, Sweden). Focused 
proteins were separated  in the second dimension on 12.5% discon- 
tinuous gels according to O'Farrell (13). After electrophoresis, the 
gels were fixed in 10% TCA/30% ethanol for 45 min, washed 
twice in 5% TCA/30% ethanol, and soaked in Amplify (Amer- 
sham Corp., Arlington Heights, IL). Dried gels were analyzed  by 
autoradiography at -800C using preflashed  Kodak X-O-Mat film 
with intensifying screens. The isoelectric points given were deter- 
mined by comparison with stained protein standards (Pharmacia 
LKB, Uppsala, Sweden). Isoelectric points given are not corrected 
for the inhibitory effects of the 9.2 M urea on hydrogen ion ac- 
tivity and should not be considered identical to isoelectric points 
obtained under physiologic  (i.e., aqueous) conditions (14, 15). Im- 
mune precipitation  of  biosynthetically  labeled  TNF from the mono- 
cyte culture supernatants was performed in an identical fashion and 
analyzed  by one-dimensional  electrophoresis on 12.5% SDS-PAGE 
gels, followed by fixation and autoradiography as above. 
Analysis of Acylated Proteins.  Recombinant human TNF (10/zg) 
was added as a carrier protein to [3H]myristate-labeled  TNF im- 
mune precipitants and separated  by SDS-PAGE on 12.5% gels. The 
TNF protein was identified by Coomassie blue staining, cut out, 
electroeluted from the gel slice, and concentrated by lyophiliza- 
tion. The samples were subjected to acid methanolysis by heating 
to 110~  for 60 h in 83% methanol/2 M HC1, containing 200 
/~g each of myristic and palmitic acid. The reaction products were 
extracted three times with petroleum ether, and 400 #g each of 
methyl myristate and methyl palmitate was added. The samples 
were  evaporated under  argon,  resuspended in  methanol,  and 
identified by analytic HPLC on a 4.6  x  25-mm ODS-5 column 
(Bio-Rad Laboratories, Richmond, CA). The column was devel- 
oped with 80% (vol/vol) acetonitrile (ACN)/0.1%  TFA/0.06% 
triethylamine (TEA) at a flow rate of I ml/min. Serial fractions 
were collected,  and the radioactivity  was quantitated by liquid scin- 
tillation counting. The dution profile  of  the radioactivity  was com- 
pared with the absorbance (210 nm) elution profiles of standard 
palmitic and myristic acids and the respective methyl esters. 
In Vitro Aoflation of Synthetic Peptides.  A series of synthetic pep- 
tides containing potentially reactive lysine residues (Table 1) were 
prepared and purified by reverse-phase HPLC. Chemically my- 
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tides with the symmetric anhydride of myristic acid, according to 
Towler and Glaser (16). The chemically acylated standard peptides 
were treated with 1 M hydroxylamine to cleave any ester-linked 
fatty acid, extracted with petroleum ether, and analyzed by reverse- 
phase HPLC and gas-phase sequencing (see below). 
The enzymatic myristyl acylation of synthetic peptides was based 
on the method of Towler and Glaser (16). In brief, myristyl CoA 
was prepared by reacting 5 nmol myristic acid with 10 nmol LiCoA, 
in an acylation buffer containing  10 mM Tris/HCl, pH 7.4, 0.1 
mM EDTA, 1 mM DTT, 5 mM MgCI2 and 250 nM ATP. There- 
after, 15 mU Pseudomonas  CoA synthetase (Sigma Chemical Co.) 
was added and the mixture incubated for 30 rain at 30~  in a final 
reaction volume of 50/~1. To this was subsequently added 10 nmol 
of synthetic peptide and 50/~g of monocyte cellular lysate in a buffer 
of 10 mM Tris/HC1, pH 7.4, 0.1 mM EDTA, and 1 mM DTT. 
A battery of protease inhibitors  (8 #M leupeptin,  1 mM PMS-F, 
and 10/~g/ml pepstatin) was added and the reaction volume was 
brought to 110/~1. The enzymatic acylation of the synthetic pep- 
tides was continued  for 10 min at 30~  followed by the addition 
of 110/~1 methanol  and 10/~1 saturated TCA. This mixture was 
incubated on ice for 10 min to precipitate cellular proteins, cen- 
trifuged  for 10 rain at 10,000 g, and the supernates (containing 
the synthetic peptides) were extracted with petroleum ether three 
times to remove unreacted myristic acid before analysis by reverse- 
phase HPLC. Standard and chemically acylated synthetic peptides 
were used to calibrate a 4.6 x 250-mm C4 RP304 (Bio-Rad Labora- 
tories) reverse-phase HPI.C column using a linear gradient of ACN 
(1%/rain)  in 0.1% TFA. The column eluates were monitored  at 
215 nm. 
To confirm the sites of peptide myristyl acylation after the enzy- 
matic reaction, gas phase sequencing was performed. As myristyhted 
lysine residues are hydrophobic and elute from the sequencer at 
a higher solvent concentration  than nonacylated residues, it is pos- 
sible to localize within the peptide sequence the actual site of ac- 
ylation (as determined by the reduced yield of nonderivatized amino 
acid). In addition to this indirect determination,  a fraction of the 
products from the gas-phase sequencer was diverted during each 
cycle and directly analyzed for N-e-NH2-myristyl  lysine content, 
using  a quantitative  HPLC assay. For  this  assay, standard  N-e- 
NH2-myristyl lysine was prepared by reaction of N-c~-BOC-lysine 
(Sigma Chemical Co.) with the symmetric anhydride of myristic 
acid as above, followed by removal of the N-cc-BOC  protecting 
group by TFA hydrolysis. Standard N-e-NHz-myristyl  lysine was 
used to calibrate a 150  x  2.l-ram ODS-222 column  (Brownlee 
Labs, Santa Clara, CA), using a linear gradient of ACN (1%/rain) 
in a buffer consisting of  water/0.1% TFA/0.06% TEA. The column 
Table  1.  Synthetic  Peptides  for TNF In Vitro Myristylation Assay 
Peptide  Sequence 
E14  E  ALKK  T  GGPQGStL2s 
tLs3  T  P  S DK  P  VAH92 
Y136  S  QVL  F  K  GQG145 
Qlu  TKVN  L  L  S A  I K  S P177 
Glss AE  AK  PWYEP194 
The amino acid sequences  of the five synthetic peptides designed to span 
all lysine residues (boldface)  in the TNF precursor are shown. 
elutate was monitored at 214 nm; N-e-NH2-myristyl lysine elutes 
at 51% ACN. 
Results 
Prior studies from our laboratories have documented the 
cotranslational myristyl acylation of the intracellular mono- 
cyte II.-1 o~ and 3  precursor proteins (5). Two-dimensional 
autoradiograms revealed that multiple intracellular monocyte 
proteins are myristyl acyhted, in addition to the II:l precursors. 
As shown in Fig. 1 A, incubation of freshly isolated human 
monocytes with [3H]myristate for 4 h leads to the labding 
of a prominent  25-26-kD  protein with  an apparent  pI of 
"~6.3. Stimulation of the monocytes for 4 h with 100 ng/ml 
lipid A before electrophoretic analysis resulted in a three- to 
fourfold increase in [3H]myristate labeling of the 25-26-kD 
protein, as determined by quantitative densitometry (Fig.  1 
B). The myristyl labeling of this particular protein is a cotrans- 
lational,  or rapid posttranslational  event, as no myristyl ra- 
diolabding occurred when the incubations were performed 
in the presence of 10 #g/ml cycloheximide (Fig. 1 C). Con- 
cordant labeling  of the 25-26-kD  protein with  [3H]myri- 
state and [3SS]methionine  was readily apparent  using incu- 
bation times as short  as 1 h  (not  shown). 
Studies by Panuska and colleagues (15), using a similar two- 
dimensional dectrophoresis protocol, have identified a 25-26- 
kD,  pI 6.3 protein present  within  [3SS]methionine-labded 
human monocytes as the TNF precursor protein, based on 
specific immune precipitations.  This observation suggested 
that the prominent 25-26-kD myristate-labeled protein ob- 
served in our experiments represented the precursor of TNF. 
This was confirmed, as shown in Fig. 2 A. Using a murine 
monoclonal anti-human  TNF antibody, it was possible to 
specifically  recover the [3H]myristate-labeled 25-26-kD,  pI 
6.3 protein from monocyte lysates. This recovery was specific 
and was completely inhibited by competition  experiments 
using an excess of nonlabeled recombinant TNF protein (not 
shown).  We  next  determined  whether  the  secreted,  or 
processed, 17-kD form of TNF is myristyl acylated. Freshly 
isolated monocytes were stimulated for 4 h with 100 ng/ml 
lipid A, during which time radiolabeling was accomplished 
with either [3SS]cysteine or [3H]myristate.  The culture su- 
pernates were subjected to immune precipitation using the 
monoclonal  anti-TNF  antibody and the products analyzed 
by  one-dimensional  SDS-PAGE  and  autoradiography.  A 
[3SS]cysteine-labeled,  17-kD  protein  was  readily  immune 
predpitated from the supernates of stimulated monocytes using 
the monoclonal TNF antibody (Fig. 2 B, lane I). The mo- 
lecular mass of this protein is consistent with its identification 
as the mature,  or processed, extracellular form of TNF.  In 
contrast, it was not possible to recover from such supernates 
a [3H]myristateqabeled 17-kD protein (Fig. 2 B, lane 2). Ex- 
posure of such material for periods of 3 mo and greater did 
not reveal any significant radioactivity in these fractions. These 
experiments  suggest that myristyl acylation is restricted to 
a component of the 25-26-kD TNF precursor that is removed 
during  the process of secretion. 
To confirm that the radiohbel present on the TNF precursor 
1055  Stevenson  et al. Figure 1.  Two-dimensional autoradiograms of human 
monocyte l)sates labeled with [3H]myristate. (A) Lysates 
from freshly isolated monocytes after a 4-h incubation with 
[3H]myristate.  The prominent 26-kD protein (denoted 
with an asterisk)  falls within the pI 6.5-6.0 range.  (B) 
Lysates from monocytes incubated for 4 h with 100 ng/ml 
lipid A in the presence of [3H]myristate. (C) L)sates from 
monocytes incubated for 4 h  with  100 ng/ml lipid A, 
[3H]myristate,  and 10/~g/ml cycloheximide. 
protein represented intact, covalently linked myristate, acid 
methanolysis of the isolated  [3H]myristate-labeled  protein 
was performed. After recovery of labeled TNF from SDS- 
PAGE gels, covalently bound fatty acid was hydrolyzed in 
acid/methanol  to  form  methyl esters  suitable  for  HPLC 
identification and quantitation. The resultant HPLC separa- 
tion of the recovered TNF-bound fatty acid is shown in Fig. 
3. Approximately  85% of the radioactivity was recovered with 
the myristyl and methyl myristate fractions. A small amount 
of radioactivity was identified as either palmitate or methyl 
palmitate. The myristyl-labeled TNF protein was resistant 
to hydrolysis with 1 M hydroxylamine (not shown), com- 
patible with linkage in the amide as opposed to thioester form. 
These data suggested that myristic acid is covalently linked 
to the NHrterminal propiece of the 26-kD TNF precursor 
by an amide bond. Nearly all myristylated proteins studied 
to date have been found to be acylated on NH~.-terminal gly- 
cine residues. Examination of the amino acid sequence of TNF 
did not reveal a glycine in position no. 2 that could function 
as a substrate for NH2-terminal myristylation. We therefore 
considered the possibility that myristylation occurs at an avail- 
able internal amino group, i.e., the e-NHz side group of ly- 
sine. The 26-kD TNF precursor contains a total of seven ly- 
sine residues.  Only  two  of these  (K19K20) are  contained 
within the 76-amino acid NH2-terminal  propiece, which we 
considered the likely site of acylation.  To determine which 
of these seven lysines were myristylated, we used an in vitro 
assay developed by Towler and Glaser (16) for the character- 
ization of the glycine specific, N-myristyl transferase. In this 
assay, synthetic peptides containing potentially reactive amino 
acids were combined with myristyl-CoA and a source of 
acyltransferase (usually a cell lysate). Cellular proteins were 
Figure 2.  (A) Two-dimensional autoradiograrn  of [3H]myristate-hbeled 
monocyte lysates after immune precipitation with monoelonal anti-TNF 
IgG. Specifically recovered is the 26-kD, pI 6.5-6.0 TNF precursor pro- 
tein. (B) One-dimcusional autoradiogram of [3sS]c)steine-labeled mono- 
cyte supernates after immune precipitation  with monoclonal anti-TNF IgG 
(lane 1) with recovery of the 17-kD extracelhlar TNF protein. A radiola- 
beled 17-kD TNF protein was not recovered from the supernates of mono- 
cytes incubated with [3H]myristate  (lane 2). 
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Figure 3.  Acid methanol)sis of [3H]myristate-labeled  TNE  Radiola- 
beled 26-kD TNF precursor protein was recovered as detailed in Materials 
and Methods, and subjected to acid methanolysis.  The resulting methyl 
esters and fatty acids were separated by analytic reverse-phase HPLC, and 
the radioactivity  in each fraction was quantified.  The bulk (85%) of the 
radioactivity was recovered as myristate and methyl myristate. 
1056  Myristyl Acylation of Tumor Necrosis Factor Figure 4.  In vitro acylation ofTNF peptide 
no. 1. (A) Elution pattern  of TNF peptide no. 
1 (filled  arrow)  by reverse-phase  HPI.C. (B) Elu- 
tion pattern  of chemically bis-acylated TNF 
peptide no. 1 (open arrow), which is more hy- 
drophobic than the unmodified peptide (filled 
arrow). (C)  Elution pattern of enzymatic,  ally 
acylated TNF peptide no. 1, revealing the for- 
mation of mono- and bis-acylated TNF pep- 
tides  (open arrows). 
precipitated  with TCA/MeOH,  free myristic acid was ex- 
tracted with petroleum ether, and the resultant  supernatants 
were analyzed by reverse-phase  HPLC. Myristylated peptides 
are more hydrophobic and elute later than their unmodified 
forms.  Enzymatically myristylated peptides were identified 
by comparison with chemically myristylated standards, which 
had been made by reacting each peptide with the symmetric 
anhydride of myristic acid. For the TNF analysis, five syn- 
thetic peptides of 10-15-amino acid length, which spanned 
all  the  lysine-containing  sequences  in  the  26-kD  TNF 
precursor, were synthesized (see Table 1) and evaluated in the 
above assay. As  a source of a potential N-e-NH2-myristyl 
transferase, cell lysates from LPS-stimulated  human mono- 
cytes were used. The reaction mixtures were then analyzed 
1057  Stevenson eta|. Figure 5.  Results  of the enzymatic in vitro acylation of TNF peptides 2-5 (A-D, respectively). In no case was an acylated end-product  detected. 
for the presence of enzymatically myristylated peptides by 
reverse-phase  HPLC. In Fig. 4 A, the elution profile of TNF 
peptide no. 1 is shown. Chemical acylation of this peptide, 
which contains two contiguous lysine residues, yielded a later 
eluting peak (Fig. 4 B), which was shown by gas-phase se- 
quencing and myristyl-lysine  determination to consist entirely 
of bis-acylated peptide. Fig. 4 C  shows the HPLC analysis 
ofTNF peptide no. 1 after reaction in the enzymatic  myristy- 
lation assay. The elution profile shows the unreacted peptide 
peak,  as well as a doublet that coelutes with the myristyl 
peptide standard. This doublet represents the mono- and bis- 
acylated forms of the peptide (see  below). In contrast to the 
results obtained with TNF peptide no. 1, it was not possible 
to demonstrate any enzymatic acylation of TNF peptides nos. 
2-5 (Fig. 5). To unambiguously confirm the myristyl acyla- 
tion of the TNF peptide no.  1, gas phase sequencing and 
direct quantitation of N-e-myristyl lysine was performed on 
the later eluting, bis-acylated product. As shown in Fig. 6, 
the yields of nonderivatized lysine in cycles 6 and 7 were 
significantly decreased, consistent with the conversion of the 
lysines to the acylated forms. Direct quantitation of N-e- 
NH2-myristyl lysine confirmed the presence of the deriva- 
tized forms in sequencing cycles 6 and 7 (Fig. 7). Analysis 
of the mono-acylated product of the enzymatic reaction in- 
dicated the preferential acylation of the second lysine residue 
(K20; not shown). A time kinetic analysis of the enzymatic 
acylation of TNF peptide no.  1 is shown in Fig. 8, which 
demonstrates  the rapid  synthesis of the bis-acylated end- 
product. The reaction rate is significantly blunted by 5 rain, 
at which time nearly 3 nmol of  end-product have  accumulated. 
Discussion 
In this paper the specific enzymatic myristylation of two 
lysine residues contained within the 76-amino acid propiece 
of the 26-kD TNF precursor protein has been demonstrated. 
In addition, the studies utilizing synthetic peptides provide 
evidence  for  the  existence  of a  lysyl peptide  N-e-NH2- 
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Figure 6.  Recovery of nonderivatized  lysine by gas-phase sequencing 
of  enzymatically acylated (bis) TNF peptide no. 1. The yield of nonderiva- 
tized (i.e., nonacylated) lysines  is decreased due to the conversion to acylated, 
hydrophobic forms. Although the sequencing was performed on HPI.C- 
purified bis-acylated TNF peptide  no.  1, there  is a partial conversion of 
the acylated lysine residues during the sequencing reaction (hydrolysis) to 
the nonacylated forms. 
1058  Myristyl  Acylation of Tumor Necrosis  Factor Figure 7.  Identification by reverse-phase HPLC of N-e-NH2-myristyl lysine in bis-acylated TNF peptide no. 1 gas-phase sequencing cycles 6 and 
7 (A-D, cycles 5-8,  respectively). 
myristyl transferase activity. Myristylation of internal lysine 
residues joins a short list of co- or posttranslational  protein 
acylations that includes N-glycyl myristylation, ester-linked 
palmitylation, and modification with complex glycosylated 
phospholipid (17). Further knowledge concerning the struc- 
ture, substrate spedficities, and relationship of the lysyl N-e- 
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Time  kinetics  of  the  enzymatic  formation  of  bis-acylated  TNF 
pc'pride no. 1. The in vitro acylation assay was performed as detailed in 
Materials and Methods, with the c~ception that the reaction was ended 
at the time points indicated. Results are given as the means of triplicate 
determinations and are expressed as nanomoles of bis-acylated  end-product. 
NH2-myristyl transferase to the N-glycyl myristyl transferase 
awaits its purification and characterization. The detailed sub- 
strate characterization of the N-glycyl myristyl transferase has 
indicated a complete lack of activity against lysine (18), and 
it must therefore be assumed that the lysyl-specific activity 
observed here represents a distinct, and previously uurccog- 
nized, enzymatic entity. The careful quantitative  study of 
Towler and Glaser (19), concerning the acylation of cdlular 
proteins,  indicated  that  ",70-80%  of total  amide-linked 
myristate was in the form of myristyl glyciue. Interestingly, 
a significant amount of radioactivity was also present in an 
undefined fraction with the HPLC dution properties charac- 
teristic of myristyl lysine, suggesting that acylation of this 
residue may not be a rare event. 
The enzymatic (octanoyl) acylation of two internal lysine 
residues as a consequence of the activation ofAgkistrodon phos- 
pholipase A2 has been described (6). The functional conse- 
quence of this event was the conversion of the inactive phos- 
pholipase  A2 monomer to a catalytically  effective enzyme 
dimer that exhibited enhanced interaction with phospholipid 
monolayers. Similarly, chemical acyhtion with a series  of fatty 
acids of lysyl 6-NH2 groups in pancreatic phospholipase A2 
converted the soluble enzyme into a membrane-penetrating 
form (20). These studies also demonstrated that attachment 
of  acyl groups  to  hydrophobic  regions,  as  opposed  to 
hydrophilic regions, significantly  enhanced the degree of  mem- 
brane penercation,  and that this penetration was optimized 
by utilizing fatty acids with smaller molecular areas. Further 
insights into the potential role of the myristyl acylation of 
lysine residues may be deduced from work done on N-glycyl- 
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Species 
Human 
pig 
Sheep 
Cat 
Rabbit 
Rat 
Mouse 
E14 
E14 
E14 
E14 
E14 
E14 
E14 
E  A 
I  I 
E  A 
I 
E  V 
I 
E  A 
G  P 
E  A 
I  I 
E  A 
P 
I 
A 
K 
I 
K 
N 
P  K 
I  I 
P  K 
1  t 
P  K 
I 
p  q 
K 
K 
K 
K 
K 
K 
K 
T 
A 
I 
A 
I 
A 
I 
A 
G 
I 
G 
I 
G 
t 
G 
I 
G 
M  L  N 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
q 
Q 
Q 
Q 
Q 
q 
Q  M  F  N 
Diagram demonstrating the interspecies  amino acid homology  for the region surrounding the myristylated  lysine residues (boldface). Vertical lines 
denote strictly conserved  residues, dots denote functional conservation. 
myristylated proteins. One extensively studied function has 
been the plasma membrane targeting of myristylated pro- 
teins.  The viral proteins p60  ..... , Pr65gag, and a variant of 
p21 Ras are all myristylated, membrane-associated proteins 
(21-24). Point mutations that abolish myristylation convert 
them into soluble, cytosolic proteins, with consequent im- 
pairment of transforming ability or viral assembly. A similar 
role for myristylation has been demonstrated for several mam- 
malian proteins. The protein kinase C substrate proteins and 
the c~ subunit of the GTP inhibitory binding protein all re- 
quire binding of myristic acid in order to associate with the 
cell membrane (25-27). 
TNF-o6 active extracellularly as a 17-kD protein, is trans- 
lated as a 26-kD precursor molecule. Initially, it was thought 
that  the  NH2-terminal propiece represented an unusually 
long signal peptide, and that the molecule was processed to 
its mature form through the classical secretory pathway (28). 
However, Muller et al. (29) found that microsomes failed to 
process the TNF precursor when analyzed in an in vitro trans- 
lation system. In 1988, Kriegler et al. (9) demonstrated that 
the 26-kD TNF precursor protein exists as an integral, trans- 
membrane protein.  The orientation of the TNF precursor 
(N~yto/C~xo) was determined by differential proteolytic diges- 
tions and is consistent with classification  as a type II integral 
membrane protein (30). Type II proteins contain signal/anchor 
domains, as opposed to cleavable signal peptides, and this pre- 
sumably explains the failure of microsomal preparations to 
process the 26-kD precursor to the 17-kD form (9,  29). 
The  existence  and  biologic  activity  of  plasma  mem- 
brane-associated  TNF  has  been confirmed by subsequent 
studies. Chensue et al. (31) showed the presence of membrane- 
associated TNF on mouse peritoneal macrophages by immuno- 
histochemical and electron microscopic techniques. Perez et 
al. (11) found that transfected cells expressing a noncleavable 
mutant of 26-kD TNF on the cell surface were active in cell- 
to-cell killing, which did not require processing to the 17-kD 
form. In contrast to the findings of Kriegler et al. (9), Bak- 
ouche et al. (32) failed to detect an integral membrane 26- 
kD TNF protein in activated human monocytes, but instead 
recovered a membrane-associated, salt-elutable  17-kD protein, 
suggesting that the processed TNF molecule was linked to 
a discrete, membrane-associated TNF-binding protein. Leuttig 
et al.  (33) found evidence for both mechanisms in murine 
macrophages.  Plasma membranes contained both  an acid- 
elutable 17-kD form of TNF with the characteristics of a 
receptor-bound protein, and a 26-kD integral transmembrane 
form. The transmembrane form possessed about 60% of total 
TNF bioactivity. In summary, there appear to be two forms 
of biologically active membrane-associated TNF: an integral 
membrane protein of 26 kD and a processed, 17-kD form 
presumably bound to a receptor or binding protein. Processing 
of the 26-kD transmembrane form to the 17-kD form appar- 
ently involves the action of proteolytic enzymes located on 
the cellular surface,  (9), leaving behind the propiece within 
the membrane (34). Structural analysis of the site of myristyl 
acylation of the TNF propiece places the target lysine residues 
almost  immediately adjacent  to  a  hydrophobic stretch of 
sufficient length (24 residues) to act as a membrane-spanning 
or anchoring sequence. Examination of the interspecies ho- 
mology of the TNF myristylation site shows significant amino 
acid conservation (Table 2).  In particular, the preferentially 
myristylated lysine20 is conserved across all species, consis- 
tent with its having a conserved functional role. This site 
also conforms to the "positive-inside rule" of yon Heijne (30), 
as calculation of the charge distribution across the putative 
membrane-spanning region is consistent with the experimental 
delineation by Kriegler (9) of a type II N~o/C,xo orienta- 
tion. Given these considerations, we hypothesize that the func- 
1060  Myristyl  Acylation of Tumor Necrosis Factor tional significance of the myristylation of these lysines is to 
facih'tate  the membrane insertion or anchoring of  this sequence. 
This event could occur primarily as a consequence of a phys- 
icochemical interaction of  the acyl group with membrane phos- 
pholipids or via binding to receptors specific for myristylated 
TNF,  analogous  to  that  identified for  myristyl-p60  src  by 
Resh and Ling (35). 
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